777 SAFETY, TOLERABILITYAND PHARMACOKINETIC OF MULTIPLE ASCENDING DOSES OF THE EP-1 RECEPTOR ANTAGONIST ONO-8539, A POTENTIAL NEW AND NOVEL THERAPY TO OVERACTIVE BLADDER IN HEALTHY YOUNG AND ELDERLY SUBJECTS
Darren Wilbraham(Eli Lilly (United States)), Séverine Vincent, Takahiro Masuda(Jichi Medical University), Steve Deacon(Ono Pharmaceutical (United Kingdom)), T. Kuwayama(Ono Pharmaceutical (United Kingdom))
Cited by 5
Related Papers
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
|American Journal of Physiology-Renal Physiology|2013|481
Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia
|American Journal of Physiology-Renal Physiology|2013|308
Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice
|American Journal of Physiology-Renal Physiology|2012|158
Osmotic diuresis by SGLT2 inhibition stimulates vasopressin‐induced water reabsorption to maintain body fluid volume
|Physiological Reports|2020|135